Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
CARLSBAD, Calif., Aug. 1, 2022 /PRNewswire/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diageno...
3D Mammography Significantly Increases the Detection of Breast Cancer Concludes a Study that Reviewed Close to Half a Million Exams Published in the Journal of the American Medical Association (JAMA)
BEDFORD, Mass., June 26, 2014 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) today announced that a groundbreaking study published in the June 25, 2014 issue of the Journal of the American Medical Association (JAMA), found that Hologic's 3D Mammography (breast tomosynthesis) screening technology finds...
The Oslo Breast Cancer Screening Trial Concludes that the Use of 3D Mammography in Combination with a 2D Breast Exam Finds Significantly More Cancers than a 2D Breast Exam Alone
-- First large-scale, peer-reviewed prospective clinical study shows that adding 3D mammography to a 2D breast screening exam enables doctors to detect 40% more invasive cancers while also reducing false positives BEDFORD, Massachusetts, Jan. 29, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the...
